KZIA

Kazia Therapeutics

Kazia Therapeutics jumped 51.74% in after-hours trading Tuesday after reporting a rare immune-complete response in a patient.read more...

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory...

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner Kazia Therapeutics to Request...

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease...

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Kazia Therapeutics announces the launch of a...

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR Newswire SYDNEY, Jan. 14, 2025...

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering Kazia Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire SYDNEY, Jan. 10, 2025 SYDNEY, Jan. 10, 2025...

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with...

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast...